REDWOOD CITY, Calif.--(BUSINESS WIRE)--Programmable Medicine (“PMED”) will present preclinical results at ACR Convergence 2026 supporting development of JAK-dendranibs, a new class of myeloid-directed JAK inhibitors designed to improve…
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Programmable Medicine (“PMED”) will present preclinical results at ACR Convergence 2026 supporting development of JAK-dendranibs, a new class of myeloid-directed JAK inhibitors designed to improve the safety of rheumatoid arthritis treatment. The program combines the known value of JAK as a validated target with the myeloid selectivity of PMED’s hydroxyl dendrimer platform. “Our goal is to offer the disease control of a JAK inhibitor with an improved safet
This is a source-linked briefing. Read the original report from Businesswire .